Drugs

Articles

• protein kinase inhibitors
  29 August 2005

  protein-kinase inhibitor ; PKIs WKPD
  Definition: A protein kinase inhibitor is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that add a phosphate (PO4) group to a protein, and can modulate its function.
  Protein-kinase inhibitors are generally small molecules that show competitive inhibition with respect to ATP.
  Examples
  tyrosine kinase inhibitors (TKIs )
  References
  Bogoyevitch MA. Therapeutic promise of JNK (...)

• crizotinib
  10 June 2010

  Pfizer drug crizotinibPF-02341066 or 1066, PF-02341066, Xalkori Wikipedia
  Molecular target: ALK
  Definition: Crizotinib is an ALK inhibitor , ROS1 inhibitor and MET inhibitor .
  Crizotinib is undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, advanced non-small cell lung carcinoma (NSCLC ).
  Crizotinib is an oral ALK (anaplastic lymphoma kinase) inhibitor under study in patients with advanced NSCLC carrying the echinoderm (...)

• artemisinins
  31 May 2006

  Combinations of an artemisinin with other antimalarial drugs are now recommended treatments for Plasmodium falciparum malaria in most endemic areas.
  Several individual molecules have been proposed as targets for artemisinins, in addition to the idea that artemisinins might have many targets at the same time.
  Artemisinins could inhibit the parasite-encoded sarco-endoplasmic reticulum Ca(2+)-ATPase (SERCA) PfATP6. A polymorphism in the gene encoding PfATP6 is associated with in vitro (...)

• cisplatin
  12 March 2006

  Cisplatin, a platinating agent commonly used to treat several cancers, is associated with nephrotoxicity, neurotoxicity, and ototoxicity, which has hindered its utility.
  Cisplatin is similar to the bifunctional alkylating agents. It covalently binds to DNA and disrupts DNA function. After cisplatin enters the cells, the chloride ligands are replaced by water molecules. This reaction results in the formation of positively charged platinum complexes that react with the nucleophilic sites on (...)

• 5-FU
  12 March 2004

  5-fluoro-2’-deoxyuridine, 5-fluorouracil, fluorouracil

• cyanamide
  20 October 2003

  Microscopical synopsis
  pseudo-Lafora bodies in liver (#6307616#)

• disulfiram
  20 October 2003

  Microscopical synopsis
  pseudo-Lafora bodies in liver (#6307616#)

• sunitinib
  2 June 2009

  Definition: Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTKs) inhibitor (multiRTKs inhibitors).
  Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
  The concept was of a ATP analogue that would compete with ATP for binding to the catalytic site of receptor tyrosine kinases. This concept led (...)

• ACEIs
  22 November 2004

  angiotensin-converting enzyme inhibitors

• methotrexate
  28 November 2005

  MTX

0 | 10 | 20 | 30